CorMedix Corp (CRMD): Revenue Growth QoQ

Corporate company logo of CorMedix (CRMD)

CorMedix Inc. has achieved liquidity standards driven by operational cash flow from the sale of protective solutions. The quarterly sales trend captures this momentum, where -47.90 determines the latest valuation metric. Growth is supported by the launch of DefenCath for dialysis centers and insurance coverage. The business's uniqueness is validated by the first FDA approval of an antimicrobial catheter lock.

CRMD CorMedix Corp Sales Growth QoQ (07/04/2022 - 11/20/2026)

CRMD (CorMedix Inc): analytical breakdowns and indicator data

- stock price and consensus target price:
- stock exchange capitalization data:
- cash and cash flow metrics:
Basic company analysis:CRMD - CorMedix Inc.
Manufactured products of CorMedix

When assessing financial stability, it is critical for investors to track revenue growth rates, calculated as the percentage change in sales volume of the current quarter compared to the same period last year, to identify scaling trends. The quarterly sales growth dynamics of CorMedix Inc. (CRMD) reflect the commercial expansion of the drug in the absence of competitors, confirming the company's strong pricing power and the potential for long-term margin expansion.